Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Aug;30(2):157–171. doi: 10.1111/j.1365-2125.1990.tb03760.x

Beta-adrenoceptor partial agonists: a renaissance in cardiovascular therapy?

D G Waller 1
PMCID: PMC1368213  PMID: 1976342

Full text

PDF
171

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AHLQUIST R. P. A study of the adrenotropic receptors. Am J Physiol. 1948 Jun;153(3):586–600. doi: 10.1152/ajplegacy.1948.153.3.586. [DOI] [PubMed] [Google Scholar]
  2. Aarons R. D., Molinoff P. B. Changes in the density of beta adrenergic receptors in rat lymphocytes, heart and lung after chronic treatment with propranolol. J Pharmacol Exp Ther. 1982 May;221(2):439–443. [PubMed] [Google Scholar]
  3. Aarons R. D., Nies A. S., Gal J., Hegstrand L. R., Molinoff P. B. Elevation of beta-adrenergic receptor density in human lymphocytes after propranolol administration. J Clin Invest. 1980 May;65(5):949–957. doi: 10.1172/JCI109781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Anderson J. L., Lutz J. R., Gilbert E. M., Sorensen S. G., Yanowitz F. G., Menlove R. L., Bartholomew M. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol. 1985 Feb 1;55(4):471–475. doi: 10.1016/0002-9149(85)90396-0. [DOI] [PubMed] [Google Scholar]
  5. Arbab A. G., Turner P. Comparison of propranolol and LB 46 (prinodolol) on hyperthyroid tachycardia. Postgrad Med J. 1971 Jun;47(548):329–331. doi: 10.1136/pgmj.47.548.329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Barrios L., Geboers J., Piessens J. H., de Geest H. Effects of xamoterol a new beta-adrenoceptor partial agonist, in patients with angina pectoris. Eur J Clin Pharmacol. 1986;29(6):667–671. doi: 10.1007/BF00615956. [DOI] [PubMed] [Google Scholar]
  7. Benson M. K., Berrill W. T., Sterling G. M., Decalmer P. B., Chatterjee S. S., Croxson R. S., Cruickshank J. M. Cardioselective and non-cardioselective beta-blockers in reversible obstructive airways disease. Postgrad Med J. 1977;53 (Suppl 3):143–148. [PubMed] [Google Scholar]
  8. Berkenboom G. M., Ibrahim T., Abramowicz M., Degre S. G. Comparison of the immediate effects of two beta-blocking drugs: a nonselective and a cardioselective with modest ISA in exercise-induced angina. Cardiology. 1987;74(1):43–48. doi: 10.1159/000174173. [DOI] [PubMed] [Google Scholar]
  9. Bhatia S. J., Swedberg K., Chatterjee K. Acute hemodynamic and metabolic effects of ICI 118,587 (Corwin), a selective partial beta 1 agonist, in patients with dilated cardiomyopathy. Am Heart J. 1986 Apr;111(4):692–696. doi: 10.1016/0002-8703(86)90101-8. [DOI] [PubMed] [Google Scholar]
  10. Boden W. E., Bough E. W., Reichman M. J., Rich V. B., Young P. M., Korr K. S., Shulman R. S. Beneficial effects of high-dose diltiazem in patients with persistent effort angina on beta-blockers and nitrates: a randomized, double-blind, placebo-controlled cross-over study. Circulation. 1985 Jun;71(6):1197–1205. doi: 10.1161/01.cir.71.6.1197. [DOI] [PubMed] [Google Scholar]
  11. Bonde J., Svendsen T. L., Lyngborg K., Mehlsen J., Trap-Jensen J. Immediate haemodynamic effects of a novel partial agonist, beta 1-adrenoceptor blocking drug ICI 141,292 after intravenous administration to healthy young volunteers and patients with ischaemic heart disease. Br J Clin Pharmacol. 1987 Jan;23(1):35–40. doi: 10.1111/j.1365-2125.1987.tb03006.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Bristow M. R., Ginsburg R., Umans V., Fowler M., Minobe W., Rasmussen R., Zera P., Menlove R., Shah P., Jamieson S. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986 Sep;59(3):297–309. doi: 10.1161/01.res.59.3.297. [DOI] [PubMed] [Google Scholar]
  13. Challenor V. F., Waller D. G., George C. F. Beta-adrenoceptor antagonists plus nifedipine in the treatment of chronic stable angina pectoris. Cardiovasc Drugs Ther. 1989 Jun;3 (Suppl 1):275–285. doi: 10.1007/BF00148472. [DOI] [PubMed] [Google Scholar]
  14. Chiche P., Witchitz S., Benaim R., Chapelle M., Haïat R. Troubles du rythme cardiaque. Traitement par le LB 46, corps d'action bêta-bloquante pure. Nouv Presse Med. 1972 Feb 12;1(7):483–484. [PubMed] [Google Scholar]
  15. Colucci W. S., Alexander R. W., Williams G. H., Rude R. E., Holman B. L., Konstam M. A., Wynne J., Mudge G. H., Jr, Braunwald E. Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med. 1981 Jul 23;305(4):185–190. doi: 10.1056/NEJM198107233050402. [DOI] [PubMed] [Google Scholar]
  16. Cruickshank J. M. Coronary flow reserve and the J curve relation between diastolic blood pressure and myocardial infarction. BMJ. 1988 Nov 12;297(6658):1227–1230. doi: 10.1136/bmj.297.6658.1227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Davidson A. C., Smith S. E. Pindolol in orthostatic hypotension. Br Med J (Clin Res Ed) 1981 May 23;282(6277):1704–1704. doi: 10.1136/bmj.282.6277.1704-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Decalmer P. B., Chatterjee S. S., Cruickshank J. M., Benson M. K., Sterling G. M. Beta-blockers and asthma. Br Heart J. 1978 Feb;40(2):184–189. doi: 10.1136/hrt.40.2.184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Detry J. M., Decoster P. M., Buy J. J., Rousseau M. F., Brasseur L. A. Antianginal effects of corwin, a new beta-adrenoceptor partial agonist. Am J Cardiol. 1984 Feb 1;53(4):439–443. doi: 10.1016/0002-9149(84)90009-2. [DOI] [PubMed] [Google Scholar]
  20. Durrington P. N., Brownlee W. C., Large D. M. Short-term effects of beta-adrenoceptor blocking drugs with and without cardioselectivity and intrinsic sympathomimetic activity on lipoprotein metabolism in hypertriglyceridaemic patients and in normal men. Clin Sci (Lond) 1985 Dec;69(6):713–719. doi: 10.1042/cs0690713. [DOI] [PubMed] [Google Scholar]
  21. Dwyer E. M., Jr, Pepe A. J., Pinkernell B. H. Effects of beta-adrenergic blockade with pindolol versus placebo in coronary patients with stable angina pectoris. Am Heart J. 1982 May;103(5):830–833. doi: 10.1016/0002-8703(82)90395-7. [DOI] [PubMed] [Google Scholar]
  22. Elliott H. The influence of clinical adrenoceptor antagonism on plasma lipid profiles. Trends Pharmacol Sci. 1988 Dec;9(12):439–442. doi: 10.1016/0165-6147(88)90134-4. [DOI] [PubMed] [Google Scholar]
  23. Emorine L. J., Marullo S., Briend-Sutren M. M., Patey G., Tate K., Delavier-Klutchko C., Strosberg A. D. Molecular characterization of the human beta 3-adrenergic receptor. Science. 1989 Sep 8;245(4922):1118–1121. doi: 10.1126/science.2570461. [DOI] [PubMed] [Google Scholar]
  24. Erikssen J., Rollag A., Otterstad J. E. A new water-soluble, selective beta-blocker with intrinsic sympathomimetic activity (ICI 141.292) in angina pectoris. Acta Med Scand. 1988;223(1):35–43. doi: 10.1111/j.0954-6820.1988.tb15762.x. [DOI] [PubMed] [Google Scholar]
  25. Feleke E., Lyngstam O., Råstam L., Rydén L. Complaints of cold extremities among patients on antihypertensive treatment. Acta Med Scand. 1983;213(5):381–385. doi: 10.1111/j.0954-6820.1983.tb03755.x. [DOI] [PubMed] [Google Scholar]
  26. Frishman W., Silverman R. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 2. Physiologic and metabolic effects. Am Heart J. 1979 Jun;97(6):797–807. doi: 10.1016/0002-8703(79)90016-4. [DOI] [PubMed] [Google Scholar]
  27. George C. F., Robertson D. Clinical consequences of abrupt drug withdrawal. Med Toxicol Adverse Drug Exp. 1987 Sep-Oct;2(5):367–382. doi: 10.1007/BF03259954. [DOI] [PubMed] [Google Scholar]
  28. Golightly L. K. Pindolol: a review of its pharmacology, pharmacokinetics, clinical uses, and adverse effects. Pharmacotherapy. 1982 May-Jun;2(3):134–147. doi: 10.1002/j.1875-9114.1982.tb04521.x. [DOI] [PubMed] [Google Scholar]
  29. Groth S., Tønnesen P., Asted M., Dirksen H., Sørensen P. G. Assessment of the relative safety of the beta-blockers ICI 141,292 and atenolol in patients with bronchial asthma. Eur J Clin Pharmacol. 1986;30(6):653–658. doi: 10.1007/BF00608211. [DOI] [PubMed] [Google Scholar]
  30. Hashimoto T., Shiina A., Toyo-Oka T., Hosoda S., Kondo K. The cardiovascular effects of xamoterol, a beta 1-adrenoceptor partial agonist, in healthy volunteers at rest. Br J Clin Pharmacol. 1986 Mar;21(3):259–265. doi: 10.1111/j.1365-2125.1986.tb05188.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Hill R. C., Turner P. Preliminary investigations of a new beta-adrenoceptive receptor blocking drug, LB46, in man. Br J Pharmacol. 1969 Jun;36(2):368–372. doi: 10.1111/j.1476-5381.1969.tb09511.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Ikäheimo M. J., Takkunen J. T. The effects of beta 1-adrenoceptor partial agonist ICI 118.587 on left ventricular function in patients with coronary heart disease. Int J Cardiol. 1984 Mar;5(3):339–349. doi: 10.1016/0167-5273(84)90111-6. [DOI] [PubMed] [Google Scholar]
  33. Jacob A. S., Hafer J. G., Jr Selective (beta-1) blockade in congestive cardiomyopathy. Am Heart J. 1983 May;105(5):872–873. doi: 10.1016/0002-8703(83)90261-2. [DOI] [PubMed] [Google Scholar]
  34. James M. A., Papouchado M., Jordan S. C. Beta blocker treatment for angina with associated bradycardia. Br Med J (Clin Res Ed) 1986 Dec 6;293(6560):1476–1476. doi: 10.1136/bmj.293.6560.1476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Jennings G., Bobik A., Korner P. Influence of intrinsic sympathomimetic activity of beta-adrenoceptor blockers on the heart rate and blood pressure responses to graded exercise. Br J Clin Pharmacol. 1981 Sep;12(3):355–362. doi: 10.1111/j.1365-2125.1981.tb01226.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Jennings G., Bobik A., Oddie C., Restall R. Cardioselectivity, kinetics, hemodynamics, and metabolic effects of xamoterol. Clin Pharmacol Ther. 1984 May;35(5):594–603. doi: 10.1038/clpt.1984.82. [DOI] [PubMed] [Google Scholar]
  37. Kowalski M. T., Haworth D., Lu X., Thomson D. S., Barnett D. B. Comparison of the effects of xamoterol and isoprenaline on rat cardiac beta-adrenoceptors: studies of function and regulation. Br J Pharmacol. 1990 Jan;99(1):27–30. doi: 10.1111/j.1476-5381.1990.tb14648.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Kullmer T., Kindermann W., Urhausen A., Hess M. Influence of xamoterol, a partial beta 1-selective agonist, on physical performance capacity and cardiocirculatory, metabolic and hormonal parameters. Eur J Clin Pharmacol. 1988;34(3):255–262. doi: 10.1007/BF00540952. [DOI] [PubMed] [Google Scholar]
  39. Lambertz H., Meyer J., Erbel R. Long-term hemodynamic effects of prenalterol in patients with severe congestive heart failure. Circulation. 1984 Feb;69(2):298–305. doi: 10.1161/01.cir.69.2.298. [DOI] [PubMed] [Google Scholar]
  40. Lammers J. W., Folgering H. T., van Herwaarden C. L. Ventilatory effects of long-term treatment with pindolol and metoprolol in hypertensive patients with chronic obstructive lung disease. Br J Clin Pharmacol. 1985 Sep;20(3):205–210. doi: 10.1111/j.1365-2125.1985.tb05062.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Lammers J. W., Müller M. E., Folgering H. T., van Herwaarden C. L. A comparative study on the ventilatory and haemodynamic effects of xamoterol and atenolol in asthmatic patients. Br J Clin Pharmacol. 1986 Nov;22(5):595–602. doi: 10.1111/j.1365-2125.1986.tb02940.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Lands A. M., Arnold A., McAuliff J. P., Luduena F. P., Brown T. G., Jr Differentiation of receptor systems activated by sympathomimetic amines. Nature. 1967 May 6;214(5088):597–598. doi: 10.1038/214597a0. [DOI] [PubMed] [Google Scholar]
  43. Leonetti G., Sampieri L., Cuspidi C., Terzoli L., Rupoli L., Fruscio M., Gradnik R., Zanchetti A. Does beta 1-selective agonistic activity interfere with the antihypertensive efficacy of beta 1-selective blocking agents? J Hypertens Suppl. 1985 Dec;3(3):S243–S245. [PubMed] [Google Scholar]
  44. Lund-Johansen P. Central haemodynamic effects of beta blockers in hypertension. A comparison between atenolol, metoprolol, timolol, penbutolol, alprenolol pindolol and bunitrolol. Eur Heart J. 1983 Jul;4 (Suppl 500):1–12. doi: 10.1093/eurheartj/4.suppl_d.1. [DOI] [PubMed] [Google Scholar]
  45. Lund-Johansen P., Omvik P., Haugland H. The first dose hemodynamic responses to Visacor (ICI 141-292) in essential hypertension. Acta Med Scand Suppl. 1985;693:121–125. doi: 10.1111/j.0954-6820.1985.tb08790.x. [DOI] [PubMed] [Google Scholar]
  46. Löfdahl C. G., Svedmyr N. Effects of xamoterol (ICI 118,587) in asthmatic patients. Br J Clin Pharmacol. 1984 Oct;18(4):597–601. doi: 10.1111/j.1365-2125.1984.tb02510.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Man in 't Veld A. J., Schalekamp M. A. How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism. Br J Clin Pharmacol. 1982;13(Suppl 2):245S–257S. doi: 10.1111/j.1365-2125.1982.tb01922.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Mann S., Craig M. W., Balasubramanian V., Raftery E. B. Once daily beta-adrenoceptor blockade in hypertension: an ambulatory assessment. Br J Clin Pharmacol. 1981 Aug;12(2):223–228. doi: 10.1111/j.1365-2125.1981.tb01204.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Marshall A. J., Roberts C. J., Barritt D. W. Raynaud's phenomenon as side effect of beta-blockers in hypertension. Br Med J. 1976 Jun 19;1(6024):1498–1499. doi: 10.1136/bmj.1.6024.1498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. McCaffrey P. M., Riddell J. G., Shanks R. G. An assessment of the partial agonist activity of Ro 31-1118, flusoxolol and pindolol in man. Br J Clin Pharmacol. 1987 Nov;24(5):571–580. doi: 10.1111/j.1365-2125.1987.tb03215.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Molajo A. O., Bennett D. H. Effect of xamoterol (ICI 118587), a new beta1 adrenoceptor partial agonist, on resting haemodynamic variables and exercise tolerance in patients with left ventricular dysfunction. Br Heart J. 1985 Jul;54(1):17–21. doi: 10.1136/hrt.54.1.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Molajo A. O., Coupe M. O., Bennett D. H. Effect of Corwin (ICI 118587) on resting and exercise heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. Br Heart J. 1984 Oct;52(4):392–395. doi: 10.1136/hrt.52.4.392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Northcote R. J. Beta blockers, lipids, and coronary atherosclerosis: fact or fiction? Br Med J (Clin Res Ed) 1988 Mar 12;296(6624):731–732. doi: 10.1136/bmj.296.6624.731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Nuttall A., Snow H. M. The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist. Br J Pharmacol. 1982 Oct;77(2):381–388. doi: 10.1111/j.1476-5381.1982.tb09309.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Ohlsson O., Lindell S. E. The effects of pindolol and prazosin on hand blood flow in patients with cold extremities and on treatment with beta-blockers. Acta Med Scand. 1981;210(3):217–219. doi: 10.1111/j.0954-6820.1981.tb09804.x. [DOI] [PubMed] [Google Scholar]
  57. Paul V., Griffith M., Ward D. E., Camm A. J. Adjuvant xamoterol or metoprolol in patients with malignant ventricular arrhythmia resistant to amiodarone. Lancet. 1989 Aug 5;2(8658):302–305. doi: 10.1016/s0140-6736(89)90488-1. [DOI] [PubMed] [Google Scholar]
  58. Port S., Cobb F. R., Jones R. H. Effects of propranolol on left ventricular function in normal men. Circulation. 1980 Feb;61(2):358–366. doi: 10.1161/01.cir.61.2.358. [DOI] [PubMed] [Google Scholar]
  59. Pouleur H., Rousseau M. F., Mengeot P., Veriter C., Vincent M. F., Brasseur L. A. Improvement of global and regional left ventricular function in patients with previous myocardial infarction by a new beta 1 adrenoceptor partial agonist, ICI 118,587. Eur Heart J. 1982 Dec;3 (Suppl 500):123–127. [PubMed] [Google Scholar]
  60. Prichard B. N., Tomlinson B., Walden R. J., Bhattacharjee P. The beta-adrenergic blockade withdrawal phenomenon. J Cardiovasc Pharmacol. 1983;5 (Suppl 1):S56–S62. doi: 10.1097/00005344-198300051-00009. [DOI] [PubMed] [Google Scholar]
  61. Prichard B. N., Walden R. J. The syndrome associated with the withdrawal of beta-adrenergic receptor blocking drugs. Br J Clin Pharmacol. 1982;13(Suppl 2):337S–343S. doi: 10.1111/j.1365-2125.1982.tb01938.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Pringle T. H., O'Connor P. C., McNeill A. J., Finch M. B., Riddell J. G., Shanks R. G. Effects of ICI 141,292 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. Br J Clin Pharmacol. 1986 Mar;21(3):249–258. doi: 10.1111/j.1365-2125.1986.tb05187.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Quyyumi A. A., Wright C., Mockus L., Fox K. M. Effect of partial agonist activity in beta blockers in severe angina pectoris: a double blind comparison of pindolol and atenolol. Br Med J (Clin Res Ed) 1984 Oct 13;289(6450):951–953. doi: 10.1136/bmj.289.6450.951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Roberts D. H., Tsao Y., McLoughlin G. A., Breckenridge A. Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. Lancet. 1987 Sep 19;2(8560):650–653. doi: 10.1016/s0140-6736(87)92441-x. [DOI] [PubMed] [Google Scholar]
  65. Rodger J. C., Sheldon C. D., Lerski R. A., Livingstone W. R. Intermittent claudication complicating beta-blockade. Br Med J. 1976 May 8;1(6018):1125–1125. doi: 10.1136/bmj.1.6018.1125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Rousseau M. F., Cheron P., Vincent M. F., Pouleur H., Lavenne F. Intérêt du xamotérol dans l'insuffisance cardiaque modérée d'étiologie ischémique. Ann Cardiol Angeiol (Paris) 1984 May-Jun;33(4):215–218. [PubMed] [Google Scholar]
  67. Rude R. E. Pharmacologic support in cardiogenic shock. Adv Shock Res. 1983;10:35–49. [PubMed] [Google Scholar]
  68. Sasayama S., Yokawa S., Akiyama M., Mikawa M., Sakai O. Cardiovascular effects of ICI 118,587, a new beta-adrenoceptor partial agonist in man. Jpn Circ J. 1986 Jul;50(7):636–643. doi: 10.1253/jcj.50.636. [DOI] [PubMed] [Google Scholar]
  69. Sato H., Inoue M., Matsuyama T., Ozaki H., Shimazu T., Takeda H., Ishida Y., Kamada T. Hemodynamic effects of the beta 1-adrenoceptor partial agonist xamoterol in relation to plasma norepinephrine levels during exercise in patients with left ventricular dysfunction. Circulation. 1987 Jan;75(1):213–220. doi: 10.1161/01.cir.75.1.213. [DOI] [PubMed] [Google Scholar]
  70. Sbirrazzuoli V., Drici M., Garraffo R., Candito M., Gibelin P., Morand P., Lapalus P. Changes in lymphocyte beta-adrenoceptor density after dilevalol oral treatment. Drugs Exp Clin Res. 1989;15(5):223–229. [PubMed] [Google Scholar]
  71. Simon G., Wittig V. J. Antihypertensive and hormonal responses to beta-blockade with intrinsic sympathomimetic activity: pindolol versus epanolol. J Cardiovasc Pharmacol. 1987 Nov;10(5):543–547. doi: 10.1097/00005344-198711000-00008. [DOI] [PubMed] [Google Scholar]
  72. Smith H. J., Halliday S. E., Earl D. C., Stribling D. Effects of selective (beta-1 and beta-2) and nonselective beta adrenoceptor antagonists on the cardiovascular and metabolic responses to isoproterenol: comparison with ICI 141,292. J Pharmacol Exp Ther. 1983 Jul;226(1):211–216. [PubMed] [Google Scholar]
  73. Smith R. S., Warren D. J. Effect of beta-blocking drugs on peripheral blood flow in intermittent claudication. J Cardiovasc Pharmacol. 1982 Jan-Feb;4(1):2–4. doi: 10.1097/00005344-198201000-00002. [DOI] [PubMed] [Google Scholar]
  74. Swedberg K., Hjalmarson A., Waagstein F., Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet. 1979 Jun 30;1(8131):1374–1376. doi: 10.1016/s0140-6736(79)92010-5. [DOI] [PubMed] [Google Scholar]
  75. Sybertz E. J., Baum T., Pula K. K., Nelson S., Eynon E., Sabin C. Studies on the mechanism of the acute antihypertensive and vasodilator actions of several beta-adrenoceptor antagonists. J Cardiovasc Pharmacol. 1982 Sep-Oct;4(5):749–758. doi: 10.1097/00005344-198209000-00009. [DOI] [PubMed] [Google Scholar]
  76. Tangø M., Carlsen J. E., Trap-Jensen J. Immediate central and regional haemodynamic effects of a new beta 1-adrenergic stimulating drug, xamoterol (Corwin) in healthy volunteers. Eur J Clin Pharmacol. 1985;29(2):155–158. doi: 10.1007/BF00547414. [DOI] [PubMed] [Google Scholar]
  77. Upward J. W., Waller D. G., George C. F. Class II antiarrhythmic agents. Pharmacol Ther. 1988;37(1):81–109. doi: 10.1016/0163-7258(88)90021-6. [DOI] [PubMed] [Google Scholar]
  78. Virk S. J., Anfilogoff N. H., Lawson N., Sadler A. M., Smith S. J., Nuttall A., Murray R. G., Littler W. A., Davies M. K. The acute effects of intravenous xamoterol ('Corwin', I.C.I. 118, 587) on resting and exercise haemodynamics in patients with mild to moderate heart failure. Eur Heart J. 1989 Mar;10(3):227–234. doi: 10.1093/oxfordjournals.eurheartj.a059470. [DOI] [PubMed] [Google Scholar]
  79. Waller D. G., Webster J., Sykes C. A., Bhalla K. K., Wray R. Clinical efficacy of xamoterol, a beta 1-adrenoceptor partial agonist, in mild to moderate heart failure. U.K. Xamoterol Study Group. Eur Heart J. 1989 Nov;10(11):1003–1010. doi: 10.1093/oxfordjournals.eurheartj.a059412. [DOI] [PubMed] [Google Scholar]
  80. Weidmann P., Uehlinger D. E., Gerber A. Antihypertensive treatment and serum lipoproteins. J Hypertens. 1985 Aug;3(4):297–306. doi: 10.1097/00004872-198508000-00001. [DOI] [PubMed] [Google Scholar]
  81. Yabuochi Y., Kinoshita D. Cardiovascular studies of 5-(3-tert-butylamino-2-hydroxy) propoxy-3,4-dihydrocarbostyril hydrochloride (OPC-1085), a new potent beta-adrenergic blocking agent. Jpn J Pharmacol. 1974 Dec;24(6):853–861. doi: 10.1254/jjp.24.853. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES